Stock markets, useful tool to provide liquidity to investors in biotech companies.

In its fifth edition, the event brought together nearly 280 attendees from more than 180 entities from 19 countries, including 70 investors from more than 55 investment entities. A total of 300 one-to-one meetings were held.

BME, in addition to meeting with companies in the sector, participated in the round table dedicated to how stock markets can be useful in providing a liquidity window for investors in these companies which, by their nature, are capital-intensive.  Already listed companies such as Oryzon contributed to the debate with their own experience of already having a shareholder base through the market. 

The audience was also introduced to the new BME Scaleup segment, a BME market aimed primarily at early stage companies with a proven business model and financing needs to invest in innovation, research and development.

BME's markets have broad  experience with companies part of the biotechnology sector. Without going any further, 11 biotech companies have been listed in BME Growth where they have raised 800 million euros through 83 capital increases.

Likewise, biotech’s have a promising future in the BME markets insofar as there are currently 8 companies in the sector that are being trained in the Pre-Market Environment with the intention of becoming a listed company in the medium term.